Faeth Therapeutics (FTH) Depreciation & Amortization (CF) (2020 - 2026)

Faeth Therapeutics (FTH) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $25000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 21.88% year-over-year to $25000.0; the trailing twelve-month figure through Jun 2026 stood at $114000.0 (down 70.77% YoY), and the FY2025 full-year result was $122000.0, down 79.67% from the prior year.
• Depreciation & Amortization (CF) declined to $25000.0 in Q2 2026 per FTH's latest filing, from $29000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $188000.0 in Q4 2024 and bottomed at $25000.0 in Q2 2026.
• Historically, Depreciation & Amortization (CF) has averaged $110555.6 across 5 years, with a median of $137500.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 60.2% in 2022, then sank 84.04% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $162000.0 in 2022, then rose by 1.23% to $164000.0 in 2023, then gained by 14.63% to $188000.0 in 2024, then tumbled by 84.04% to $30000.0 in 2025, then decreased by 16.67% to $25000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $25000.0, $29000.0, and $30000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.